Review ArticlesLosartan A Novel Treatment for Acute Skeletal Muscle InjuryHubbert, Katherine MHS, PA-C1; Clement, Ryan PA-C1Author Information 1Duke University, Durham, North Carolina Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSJOPA/A136). JBJS Journal of Orthopaedics for Physician Assistants: April-June 2021 - Volume 9 - Issue 2 - e20.00030 doi: 10.2106/JBJS.JOPA.20.00030 Buy Metrics Abstract Skeletal muscle injury is a common and debilitating orthopaedic condition. Unfortunately, current treatment protocols inadequately facilitate full muscular recovery. New research is investigating modalities that regulate postinjury muscle fibrosis or scar tissue, which in excess can increase muscle stiffness and risk of reinjury. Losartan, a well-known angiotensin II receptor blocker, reduces muscle fibrosis after acute muscle injury in animal models by indirectly inhibiting transforming growth factor-β1, a profibrotic growth factor released during muscle healing. Although promising results have been shown thus far, additional human clinical trials are needed to confirm these findings and provide guidance on treatment. Copyright © 2021 by The Journal of Bone and Joint Surgery, Incorporated.